| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
There is an antioxidant in dihydrolipoic acid. At a rate of around 3.3×105 M-1 s-1, DHLA may scavenge OH radicals and superoxide dilution. Dihydrolipoic acid is a highly effective antioxidant, which is crucial as O2-is a more selective alternation that is quite mild and may be utilized to differentiate between substrates' varying levels of antioxidant capacity [1].
|
|---|---|
| ln Vivo |
Treatment with dihydrolipoic acid (DHLA) can stop LPS-induced sickness behavioral episodes. In LPS-induced illness behavior events, dihydrolipoic acid decreased the expression of NLRP3, caspase-1, and IL-1β and raised the expression of ERK, Nrf2, and HO-1. However, it decreased the quantity of ROS formation. Alpha-lipoic acid (LA), which decreases oxidation and functions as a potent antioxidant, is converted to dihydrolipoic acid [2]. Treatment with dihydrolipoic acid can reverse illness behavior brought on by LPS [2].
|
| Animal Protocol |
Animal/Disease Models: Adult male SD (SD (Sprague-Dawley)) rat (body weight, 200-220 g) [2]
Doses: 15 mg/kg, 30 mg/kg , 60 mg/kg Route of Administration: Daily intraperitoneal (ip) injection Experimental Results: Treatment with 30 mg/kg and 60 mg/kg improved body weight gain compared with the LPS group. |
| References |
|
| Additional Infomation |
Dihydrolipoic acid is a thio-fatty acid that is reduced form of lipoic acid. A potent antioxidant shown to directly destroy superoxide, hydroperoxy and hydroxyl radicals; also has neuroprotective and anti-tumour effects. It has a role as a neuroprotective agent, an antioxidant and a human metabolite. It is functionally related to an octanoic acid. It is a conjugate acid of a dihydrolipoate.
Dihydrolipoic acid has been reported in Homo sapiens with data available. |
| Molecular Formula |
C8H16O2S2
|
|---|---|
| Molecular Weight |
208.34144
|
| Exact Mass |
208.059
|
| CAS # |
462-20-4
|
| PubChem CID |
421
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
360.8±32.0 °C at 760 mmHg
|
| Melting Point |
60ºC
|
| Flash Point |
172.0±25.1 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.527
|
| LogP |
2.07
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
12
|
| Complexity |
128
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(CCC(=O)O)CC(CCS)S
|
| InChi Key |
IZFHEQBZOYJLPK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C8H16O2S2/c9-8(10)4-2-1-3-7(12)5-6-11/h7,11-12H,1-6H2,(H,9,10)
|
| Chemical Name |
6,8-bis(sulfanyl)octanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~479.98 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.83 mg/mL (3.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.83 mg/mL (3.98 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.83 mg/mL (3.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.7998 mL | 23.9992 mL | 47.9985 mL | |
| 5 mM | 0.9600 mL | 4.7998 mL | 9.5997 mL | |
| 10 mM | 0.4800 mL | 2.3999 mL | 4.7998 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
